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 The traditional view of diabetic retinopathy, based on oph-
thalmoscopic observations, is of a microangiopathic compli-
cation associated with diabetes beginning after a long period
of the disease [1]. However, more recent investigations into
the effect of diabetes on retinal neural tissue have shown that
the disease damages neurons in the inner [2-4] and outer retina
[5], induces glial cell activation [4,6-8], and reduces oscilla-
tory potentials on the electroretinogram [9] prior to the onset
of microvascular disease. Such studies suggest that virtually
all cell types in the retina are affected in the diabetic process
before the onset of retinopathy [10]. This phenomenon can be
described as diabetic retinal neuropathy.
Animal studies of the diabetic retina in the pre-retinopathic
stage show that neuronal cell death is accompanied by a re-
duction in nonangiogenic neurotrophic factors from endocrine
(insulin and erythropoietin [EPO]) [1] and paracrine (brain-
derived neurotrophic factor-BDNF [11] and pigment epithe-
lium-derived factor, PEDF) [12,13] sources, with an accom-
panying increase in locally produced angiogenic neurotrophic
factors such as vascular endothelial growth factor (VEGF)
[14,15]. Studies involving the supplementation of locally pro-
duced nonangiogenic neurotrophic factors to reduce the neu-
ronal and glial signs of diabetes in the retina support this view
[2,11,16]. In humans, supplementation of endocrine neu-
rotrophic factors has also had some success, with EPO ad-
ministration reducing signs of diabetic retinopathy in a small
cohort [17]. Moreover, the Diabetes Control and Complica-
tions Trial (DCCT) can be interpreted to show that exogenous
administration of the neurotrophic factor insulin prevents dia-
betic retinopathy [18].
The retinal pigment epithelium (RPE) is a neuroectoder-
mal monolayer of cells situated between the photoreceptors
and the choroid. The functions of the RPE are complex, but
one of its major roles is to support retinal integrity. It achieves
this in part by regulating nutrients [19], phagocytosing rod
outer segments [20], and by contributing to the production of
cytokines in the eye, including neurotrophic factors such as
fibroblast growth factor-2 (FGF-2) [21] and angiogenic fac-
tors such as VEGF [22]. While retinal and systemic produc-
tion of trophic factors have been well studied in diabetes, the
growing understanding of the contribution of different retinal
cell types to the diabetic process has led to no studies which
have investigated whether the RPE contributes to the retinal
trophic support in diabetes.
This investigation focuses on the expression of FGF-2 in
diabetes. FGF-2 is produced by the RPE [21] and its levels
are actively modulated in the tissue in response to a variety of
insults [23]. Originally thought to be important in angiogen-
esis [24], the function of FGF-2 is now thought to be not pri-
marily angiogenic in nature [25] and its main role in the cen-
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tral nervous system is now thought to be neurotrophic and
neuroprotective. Constitutive FGF-2 production in the healthy
adult is confined to the brain and retina [26,27], where it is
expressed widely [28]. Continuous production of the
neurotrophin is essential to the health of the retina, and inhibi-
tion of FGF-2 signaling in the normal retina induces retinal
degeneration in a transgenic model [29]. This is supported by
in vitro studies, which have shown that the protein enhances
survival and neurite outgrowth in a range of neural prepara-
tions [30,31]. In vivo studies in models of CNS injury reflect
the neuroprotective nature of the compound, showing FGF-2
is upregulated, and its distribution altered in models of corti-
cal [32-34] and retinal [35-37] injury. FGF-2 also shows un-
usual properties in the diabetic retina: Unlike most neurotrophic
factors with little angiogenic activity, FGF-2 is elevated in
diabetic retinopathy [38,39]. Indeed, laser photocoagulation,
a treatment known to be beneficial for diabetic retinopathy
[40], causes an increase in FGF-2 production in the retina to-
gether with its more accepted role of decreasing oxygen con-
sumption [41]. It therefore seems attractive to postulate that
the upregulation of FGF-2 in the diabetic retina is an endog-
enous mechanism for protecting neural tissue from injury and
that if a deficiency in FGF-2 production occurs in the diabetic
RPE than this could contribute to diabetic retinal neuropathy.
The investigations performed here used the well charac-
terized model of the streptozotocin-induced diabetic rat. This
model is useful because retinal neovascularization does not
occur [16] but signs of neural injury and glial cell activation
similar to those reported in human retinas (diabetic retinal
neuropathy) become evident as the disease progresses [3,7].
Thus, it can be argued that any changes in the levels of neu-
rotrophic factors in this model are predominant associated with
a response analogous to diabetic retinal neuropathy, rather than
as markers of incipient angiogenesis.
Therefore, an aim of this investigation was to isolate the
RPE from a rat model of diabetes and measure the expression
of the neurotrophic factor, FGF-2, in the tissue. In addition,
experiments were performed to explore the mechanism of any
changes in FGF-2 levels in the RPE during diabetes by inves-
tigating possible paracrine and endocrine factors likely to be
involved. These included retinal FGF-2 expression, glial cell
activation, environmental glucose levels, insulin, and insulin-
like growth factor (IGF).
METHODS
 All experiments conformed to the ARVO Statement for the
Use of Animals in Ophthalmic and Vision Research. Eighteen
age-matched adult male Listar hooded rats (200-250 g) were
housed in a temperature- and humidity-controlled room with
a 12 h light/12 h dark cycle and provided with food and water
ad libitum. Random blood glucose concentrations were mea-
sured using a Precision PCx Glucometer (Medisense UK Ltd.,
Abingdon, Oxfordshire, UK). Nine rats were randomly as-
signed to the diabetic group and given an intraperitoneal in-
jection of 62.5 mg/kg of streptozotocin in 10 mM citrate buffer.
A control group of nine rats received an intraperitoneal injec-
tion of the citrate buffer alone. Retinas were taken after 15
weeks of diabetes for analysis. One to three RPE sheets from
each eye were isolated by washing the eye cup in phosphate-
buffered saline (PBS) and then incubating the whole cup in
0.5% trypsin at 37 °C for 5 min. A flame-blunted Pasteur pi-
pette was then used to scrape the RPE sheets from each eye
into 1 ml of unsupplemented Hams F-10 containing soybean
trypsin inhibitor (type I-S, 5 mg/7.5 ml). Samples were cen-
trifuged at 2000x g at 4 °C for 5 min. The resultant pellet was
washed repeatedly in PBS (100 mM, pH 7.4) and centrifuged
again to provide samples for analysis.
Semiquantitative PCR:  The levels of cyclophilin, FGF-
2, and GFAP mRNA were determined using a semiquantitative
reverse transcriptase-polymerase chain reaction technique (RT-
PCR) as described elsewhere [42]. Primer sequences are listed
in Table 1. Briefly, total RNA was isolated, and first strand
cDNA synthesis performed on 2 µg of DNAse-treated RNA.
Aliquots of the resultant cDNA species were amplified in PCR
buffer with 4 mM MgCl2. Reactions were initiated by incu-
bating at 94 °C for 10 min and PCRs (94 °C, 15 s; 52 °C, 30 s;
72 °C, 30 s) performed for a suitable number of cycles fol-
lowed by a final extension at 72 °C for 3 min. PCR products
were separated on 1.5% agarose gels using ethidium bromide
for visualization. The relative abundance of each PCR prod-
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TABLE 1. SEQUENCE OF PRIMERS USED FOR PCR
                                          Product   Annealing            Accession
   mRNA       Primer sequences (5'-3')     size     temp (°C)   Cycles    number
-----------   -------------------------   -------   ---------   ------   ---------
Cyclophilin   TGGTCAACCCCACCGTGTTCTTCG    314 bp       52         26      M19533
              TCCAGCATTTGCCATGGACAAGA
FGF-2         GCCTTCCCACCCGGCCACTTCAAGG   179 bp       55         27      M22427
              GCACACACTCCCTTGATGGACACAA
GFAP          ATTCCGCGCCTCTCCCTGTCTC      437 bp       55         27      U03700
              GCTTCATCCGCCTCCTGTCTGT
Primers were designed online using Primer3 to span an intron, thereby eliminating genomic contamination. Parameters were set to minimize
self complementarity and maximize PCR efficiency by checking oligonucleotides for possible formation of primer-dimers, primer cross-
dimers, and hairpins. BLASTn (version 2.0) was used to ensure 100% specificity of primers to the target. PCRs were optimized for annealing
temperature and Mg2+ concentration. Analysis of gels revealed no primer-dimer formation.
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uct was determined by quantitative analysis of digital photo-
graphs of the gels viewed under UV light using Labworks
software (UVP Products, Upland, CA).
Western blotting:  Retinal and RPE proteins were isolated
simultaneously with RNA using the standard Tri-Reagent tech-
nique (Sigma, Poole, UK). After processing, samples were
solubilized in homogenization buffer with protease inhibitors
(20 mM Tris HCl, pH 7.4, containing 2 mM EDTA, 0.5 mM
EGTA, 1% SDS, 0.1 mM phenylmethylsulphonyl fluoride, 50
µg/ml aprotinin, 50 µg/ml leupeptin, and 50 µg/ml pepstatin
A). An equal volume of sample buffer (62.5 mM Tris HCl, pH
7.4, containing 4% SDS, 10% glycerol, 10% mercaptoethanol,
and 0.002% bromophenol blue) was then added. Electrophore-
sis of samples was performed using 10% polyacrylamide gels
containing 0.1% SDS and proteins blotted onto nitrocellulose
(Sigma). Blots were incubated for 3 h at room temperature
with primary antibodies against actin (Chemicon, Chandler’s
Ford, UK; monoclonal antibody, 1:2000), FGF-2 (Santa Cruz
Biotechnology, through Insight Biotechnology, Wemberly, UK;
polyclonal rabbit sc-79, 1:200), and GFAP (DAKO, Ely, UK;
polyclonal rabbit 1:400). Development was then performed
using an avidin-biotin peroxidase complex kit (Vector Labs,
Peterborough, UK; 1:100) with appropriate secondary anti-
bodies and subsequently processed according to the
manufacturer’s directions. The final nitrocellulose blots were
developed with a 0.016% w/v solution of 3-amino-9-
ethylcarbazole (AEC) in 50 mM sodium acetate (pH 5.0) con-
taining 0.05% (v/v) Tween-20 and 0.03% (v/v) H2O2. The color
reaction was stopped with 0.05% sodium azide solution and
scanned at 800 dpi by an Epson Perfection 1200u scanner.
Quantitative analysis of the files was performed using
Labworks software (UVP Products, CA).
RPE cell culture:  Postmortem donor human eyes (do-
nors aged 26 and 58 years) were obtained without their cor-
nea (for transplantation purposes) from Bristol Eye Bank
(Bristol, England) up to 48 h after enucleation and were pro-
cessed immediately. Culture procedures were undertaken in a
sterile laminar flow hood (ICN Flow, Thames, UK). Cultures
of RPE cells were prepared and characterized by labeling for
cytokeratin (KG 8.13) as described previously [43]. Culture
medium consisted of Hams-F10 supplemented with 5 mM
glucose, 10% (v/v) fetal bovine serum, 0.4% glucose, 2 mM
glutamine, amphotericin B (25 µg/mL), and gentamicin (100
µg/mL). Primary cultures were grown in 25 cm2 culture flasks
and passaged in a ratio of 1:3, and thereafter, in 75 cm2 flasks.
While growing, cultures were kept in an incubator at 37 °C,
with saturating humidity and an atmosphere of 5% carbon di-
oxide to 95% air. Experiments were performed between the
third and seventh passages.
Culture of transformed Müller cells:  The RMC-1-trans-
formed Müller cell line was obtained from Dr. V. Sarthy (North-
western University, Chicago, IL). These cells were grown in
modified Eagle’s medium (MEM) supplemented with 5 mM
glucose, 10% FBS, 2 mM glutamine, 2.5 mg/ml amphotericin
B, and 100 µg/ml gentamicin. Cells were passaged at a ratio
of 1:3 every 48-72 h and used for the outlined studies when
80% confluent.
Immunocytochemistry:  Some cells from each culture were
transferred to 13 mm glass coverslips in 24 well plates. After
appropriate treatments, cells were fixed in 4% paraformalde-
hyde in sodium phosphate buffer (100 mM, pH 7.4) for 30
min. Cells were washed in PBS and PBS plus Triton X-100
(0.1%, v/v (PBS-T)), and nonspecific antibody binding was
blocked with bovine serum albumin in PBS (0.5%, w/v; PBS-
B). Cultures were then incubated in PBS-B with primary anti-
bodies against FGF-2 (Santa Cruz Biotechnology; sc-79
polyclonal rabbit, 1:200), vimentin (Sigma, monoclonal
1:1000) and GFAP (Dako, polyclonal rabbit; 1:200). After cells
were washed three times (5 min each) in PBS-T, they were
immunolabeled with fluoroscein isothiocyanate (FITC)-linked
antirabbit or antimouse antisera (Sigma, Poole, UK; 1:100).
Visualization was by using a Zeiss epifluorescence microscope
(Göttingen, Germany).
Experimental protocol in cell culture experiments:  Ex-
periments designed to investigate the mechanism of in vivo
findings in the RPE were performed on cells grown to 80%
confluence in both RPE and Müller cell cultures. To remove
insulin from the FBS used in the growth media, appropriate
cultures were washed three times in PBS (100 mM, pH 7.4)
and maintained for two days in a hormonally defined media
(HDM) of Ham’s F10 (for RPE cells) or MEM (for Müller
cells) supplemented with 5 mM glucose, 2 mM glutamine,
2.5 mg/ml amphotericin B, 100 µg/ml gentamicin plus 1 g/l
transferrin, 96.6 µg/ml putresceine, 300 nM sodium selenate,
200 nM progesterone, and 10 pM estrogen, together with treat-
ments of glucose, mannitol, insulin, IGF-1, and the IGFR-1
inhibitor, AG1024.
Cultures used for semiquantitative analysis of protein lev-
els were grown in 6 well plates and samples collected for analy-
sis by dislodging cells with a cell scraper, centrifuging the cell
suspension at 1000x g for 5 min and then resuspending the
pellet in 100 µl of homogenization buffer and processed for
immunoblotting as already described.
Statistical analyses:  All analyses were performed with
the SPSS statistical package (v. 12; SPSS Inc., Chicago, IL).
Rat weights and blood glucose levels were analyzed using
Student’s unpaired t-tests. Other analyses of difference were
performed with Student’s unpaired t-tests. Intra- and interclass
correlations between the two eyes of each animal were ac-
counted for using repeated measures analysis of variance.
Bonferroni’s correction to the p value was included where
multiple endpoints were measured from the same samples.
Correlation coefficients were obtained from linear regressions
by the least squares method and 95% prediction intervals cal-
culated. All results are presented as mean±standard error of
the mean (SEM). Assay readings and analysis of protein lev-
els in cultures were corrected for osmotic control levels, and
the results of varying replications in four to six independent
cultures were compared using Student’s t-test or repeated
measures analysis of variance where appropriate. An α level
of 0.05 was chosen.
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RESULTS
Streptozotocin induces diabetes in the rat:  Diabetic rats dis-
played polyuria, polydipsia, and had unformed feces through-
out the experiment. Cataracts became evident in some rats in
the diabetic group after nine weeks of diabetes, and all rats
displayed cataracts on gross examination after 12 weeks of
the experiment. No cataracts were evident in the control group
at any time. Rats in the diabetic group showed reduced weight
gain, displaying an average gain of 4.5±1.6 g/week compared
with 11.2±0.4 g/week in the control group averaged across
the experiment (p<0.001). Final random blood glucose con-
centrations were 6.7±0.5 mM in the control group and 22.3±3.1
mM in the diabetic group (p<0.001). No rats from either group
died during the experiment.
Figure 1 shows analysis of retinal and RPE samples taken
from diabetic and control rats. Figure 1A shows that the RPE
samples contained no detectable neurofilament light (an inner
retinal marker found in ganglion cells) or von Willebrand fac-
tor (vWF), a marker of endothelial cells as found in the chor-
oid, revealing the relative purity of the sample. Figure 1B,C
show that FGF-2 protein and mRNA levels in retinal samples
were significantly increased by 25±6% and 34±4%, respec-
tively, in the diabetic group after 15 weeks of diabetes. GFAP
levels were also significantly increased in the diabetic retina,
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Figure 1. The effects of diabetes on FGF-2 and GFAP.  The effect of
15 weeks of diabetes on retinal and retinal pigment epithelium fibro-
blast growth factor-2 and retinal GFAP expression was measured by
immunoblotting. A: Immunoblotting for neurofilament light (NFL,
an inner retinal marker), von Willebrand Factor (vWF; monomer, an
endothelial marker), and actin (a housekeeping structural protein),
showing the method used to produce RPE samples for analysis yielded
relatively little contamination from the retina or choroid. B: Repre-
sentative immunoblots showing upregulation of FGF-2 and GFAP
protein and mRNA in the diabetic retina but downregulation of FGF-
2 protein and mRNA in the diabetic RPE. The control (C) and dia-
betic (D) lanes are identified. Cyclophilin is abbreviated “Cyclo”. C:
FGF-2 protein and mRNA was reduced by 25±6% (p<0.01) and
35±4% (p<0.01) in the diabetic RPE. In contrast, retinal FGF-2 pro-
tein and mRNA were increased by 26±7% (p<0.01) and 47±8%
(p<0.01). Similarly, GFAP expression was also increased in the dia-
betic retinas. Asterisk (*) indicates p<0.01 after accounting for intra-
and interclass variability between eyes and within animals by re-
peated measures analysis of variance; 18 eyes were studied in each
group. D: Retinal FGF-2 protein levels were not related to the FGF-
2 expression in the corresponding eye’s RPE (p<0.87). E: Retinal
GFAP levels were correlated to the FGF-2 expression in the corre-
sponding eye’s RPE (r2=0.31, p<0.01). Dotted lines indicate 95%
prediction intervals of the regression. Results are expressed propor-
tionally in relation to 5 mM glucose in the absence of insulin.
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with a 68±37% increase in mRNA and 98±16% increase in
protein expression. Figure 1B,C also show that RPE FGF-2
protein and mRNA levels were distinctly reduced in diabetes
by 25±6% and 36±7%, respectively.
In order to determine if retinal production of either pro-
tein could relate to a decrease in FGF-2 expression in the RPE,
the amount of FGF-2, and GFAP protein in individual eyes
were correlated. There was no significant correlation between
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Figure 2. Immunohistochemical characteristics of cultures.  Each pair of panels shows the cellular architecture of the culture: The top panel
presents a hematoxylin stain and the corresponding immunolabeling is beneath it. A: Cultured Müller cells grown in hormonally defined
medium (HDM) and 5 mM glucose for 24 h with no added insulin. Cells demonstrate expression of vimentin, a specific Müller cell marker,
along with GFAP and FGF-2. B: Cultured retinal pigment epithelium (RPE) cells grown in HDM and 5 mM glucose for 24 h with no added
insulin. Cells are immunoreactive to cytokeratin (K 8.13). C: Representative Müller cell GFAP labeling after 24 h of treatment. It can be seen
that cultures in 15 mM glucose display increased GFAP production relative to cultures treated in the 5 mM glucose environment. This increase
appears to be evident in all cells, however some cells appear to be more intensely labeled. D: Representative RPE cell labeling after 24 h of
treatment. It can be seen that cultures in 15 mM glucose display quantitatively increased fibroblast growth factor-2 production when treated
with 9 nM insulin. Subtly decreased FGF-2 labeling was seen after 24 h in cultures in 15 mM glucose without insulin. The scale bar represents
100 µm.
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retinal and RPE FGF-2 levels (r2=0.01, p<0.87; Figure 1D).
In contrast, there was a significant correlation between RPE
FGF-2 expression and retinal glial cell activation as indicated
©2006 Molecular VisionMolecular Vision 2006; 12:43-54 <http://www.molvis.org/molvis/v12/a5/>
Figure 3. The effect of insulin on retinal pigment epithelium (RPE) and Müller cell protein expression.  The effect of insulin on RPE and
Müller cell protein expression was measured by immunoblotting, in conditions of high (15 mM) and low (5 mM) glucose. Results are ex-
pressed as a proportion of the expression of the substance in 5 mM glucose in the absence of insulin. A,B,C: The effect of insulin on fibroblast
growth factor-2 (FGF-2) production in RPE culture. After 6 h, insulin and glucose levels have no effect on RPE FGF-2 expression. However,
after 24 h, FGF-2 production is significantly decreased (p<0.01) in conditions of low insulin but only in the 15 mM glucose environment.
Conversely, high insulin levels increased FGF-2 production in the RPE significantly in the 15 mM glucose environment relative to the 5 mM
environment (p<0.01). This effect is maintained in other cultures analyzed 48 h after treatment. In a 5 mM environment, insulin levels in this
range do not alter FGF-2 expression in cultured RPE cells at any of the times tested. D,E,F: Similar experiments in cultured Müller cells are
shown. GFAP expression in Müller cells is unaffected by insulin or glucose treatments after 6 h, however, after 24 h of treatment, very low
levels of insulin are noted to increase GFAP expression significantly in an environment of 15 mM glucose (p<0.01). GFAP expression is
decreased with increasing insulin concentrations in the 15 mM environment and is significantly reduced relative to the 5 mM environment
after treatment with 900 pM and 9 nM of insulin (p<0.05). After 48 h of treatment in other cultures, low insulin levels increased GFAP levels
to a significantly greater degree (p<0.05 at the lowest insulin levels), and the increase was significant relative to the 5 mM environment across
a greater range of concentrations. After 48 h in the 15 mM glucose environment, 9 nM insulin was still effective in reducing GFAP expression
both relative to the insulin free conditions (p<0.01) and to all treatments in the 5 mM environment. In the environment of 5 mM glucose, GFAP
expression was not significantly altered with insulin treatment across the range of concentrations and treatment durations tested here. G,H,I:
FGF-2 production in cultured Müller cells was not significantly altered by insulin in either glucose environment across the range of concentra-
tions and treatment durations investigated here. Asterisk indicates p<0.05 by Student’s unpaired t-tests comparing protein expression in the 5
and 15 mM glucose environments with five independent samples for each treatment condition and at each time.
by GFAP protein expression (r2=0.31, p<0.01; Figure 1E).
Culture experiments:  Studies on RPE and Müller cell
cultures in low (5 mM) or high (15 mM) glucose environment
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were undertaken in order to determine if the relationship be-
tween GFAP and RPE FGF-2 production in the diabetic retina
in vivo was causal or if a separate dose-dependent mechanism
was responsible for these phenomena.
The characteristics of Müller and RPE cell cultures used
in these studies are shown in Figure 2. RPE cultures at the
passages used in these studies showed immunolabeling for
cytokeratin (KG 8.13) an RPE specific protein [44], and FGF-
2 (Figure 2B,D). Müller cell cultures were positively labeled
for vimentin, GFAP, and FGF-2 (Figure 2A).
In “type 1 diabetic” conditions (15 mM glucose and no
insulin for 1 day), immunolabeling for FGF-2 in RPE cells
(Figure 2D) showed less intense staining than in conditions of
5 mM glucose. Addition of 9 nM insulin resulted in more in-
tense FGF-2 labeling in 15 mM of glucose than in 5 mM glu-
cose (Figure 2D). In the Müller cell cultures, GFAP staining
in 15 mM glucose and no insulin was more intense than when
insulin was present in either 5 mM glucose or 15 mM glu-
cose. (Figure 2C) In contrast, the intensity of FGF-2 staining
in the Müller cell culture appeared unaffected by insulin in
either a low or high glucose environment (results not shown).
Figure 3 quantifies the relationships described in Figure
2 for 6 h, 24 h, and 48 h treatment periods using
immunoblotting. A dose-dependent relationship exists between
insulin and FGF-2 production in RPE cells and GFAP sup-
pression in Müller cells, respectively. These relationships are
evident only after a 24 h period and only for cultures in the 15
mM when results are normalized with what occurs in 5 mM
glucose in the absence of insulin.
After two days of exposure to high glucose in the ab-
sence of insulin, RPE cells contained 65±23% less FGF-2 than
cells in 5 mM glucose (p<0.05) and 71±26% less FGF-2 than
cells in 15 mM glucose and treated with physiological (36-
179 pM) [45] levels of insulin (p<0.05; Figure 3C). When
cultures exposed to 15 mM glucose are treated with 9 nM
insulin, FGF-2 levels are increased 64±28% (p<0.05) relative
to the same treatment in cultures exposed to 5 mM glucose
(Figure 3C). Insulin had no significant effect on FGF-2 ex-
pression in cultures exposed to an environment of 5 mM glu-
cose (Figure 3A-C). FGF-2 levels in cells exposed to 15 mM
of glucose and treated with physiological levels of insulin (90
pM) were also not significantly different to the levels in cul-
tures maintained in 5 mM glucose (Figure 3A-C).
Insulin treatment had the opposite effect on expression of
GFAP in Müller cell cultures (Figure 3D-F). After two days of
exposure to high glucose in the absence of insulin, Müller cells
produced 83±27% more GFAP than cells in 5 mM glucose
(p<0.05) and 81±26% less GFAP than cells in 15 mM glucose
that were treated with physiological levels of insulin (p<0.05;
Figure 3F). When treated with 9 nM insulin, GFAP levels de-
creased 44±15% relative to the same treatment in cultures
exposed to 5 mM glucose. Insulin had no significant effect on
GFAP expression in cultures in an environment of 5 mM glu-
cose. Cells exposed to 15 mM glucose and treated with physi-
ological levels of insulin did not display significantly differ-
ent FGF-2 or GFAP levels than the cells maintained in 5 mM
glucose. Müller cell FGF-2 levels were not significantly af-
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Figure 4. Mechanisms of changes to FGF-2 and GFAP expression.
The effect of insulin-like growth factor and the insulin like growth
factor receptor 1 antagonist AG1024 was measured on retinal pig-
ment epithelium (RPE) fibroblast growth factor-2 (FGF-2) expres-
sion and Müller cell GFAP expression in culture. Treatment with 9
nM insulin increases FGF-2 production in this system, and this ef-
fect is mirrored by 1 nM IGF. A: Expression of FGF-2 by cultured
retinal pigment epithelium (RPE) cells after 24 h of treatment. The
two effects are not statistically different. Treatment with 30 µM
AG1024, a dose effective in blocking IGFR-1 receptors but not insu-
lin receptors [46], reduces both insulin, and IGF-induced FGF-2 ex-
pression to levels which are not significantly different to baseline in
the 15 mM glucose environment. Addition of 120 µM AG1024, a
dose which affects both IGFR-1, and insulin receptors [46] has no
additional effect in blocking insulin induced FGF-2 expression. B:
Expression of GFAP in cultured Müller cells (RMC) after 24 h of
treatment. 9 nM insulin decreases GFAP production in this system
and this effect is also evident in cultures treated with 1 nM IGF. The
effects of 9 nM insulin and 1 nM IGF are not statistically different.
AG1024 (30 µM) blocks the effect of insulin and IGF on GFAP ex-
pression to levels that are not significantly different to insulin-free
baseline in the 15 mM glucose environment. Addition of 120 µM
AG1024 has no additional effect in blocking the action of insulin on
GFAP expression in an environment of 15 mM glucose. Asterisk in-
dicates p<0.05 comparison to 15 mM glucose baseline by Student’s
unpaired t-test with five independent repetitions for each culture treat-
ment.
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fected by either glucose or insulin treatment in the ranges tested
(Figure 3G-I).
Figure 4 shows the results of investigations designed to
explore the possible mechanism by which insulin influences
RPE FGF-2 levels and Müller GFAP expression in an envi-
ronment of 15 mM glucose. Figure 4A shows that in RPE cul-
tures a significant increase (121±24%, p<0.05) in FGF-2 oc-
curs after 24 h of treatment with 9 nM insulin in a high (15
mM) glucose environment. This effect is reduced to levels not
significantly different to the insulin-free baseline by addition
of 30 µM AG1024 which is known to specifically block IGFR-
1 receptor signaling [46]. Higher concentrations of AG1024
(120 µM) also blunts the effect of insulin. This concentration
of AG1024 is known to block both IGFR-1 and insulin recep-
tors [46], and from the data shown in Figure 4A had no clear
effect on FGF-2 expression. In addition, treatment with 1 nM
IGF led to an increase in FGF-2 expression of 128±28%
(p<0.05) which was not significantly different to that induced
by treatment with 9 nM insulin (Figure 4A). This IGF-induced
increase in FGF-2 production in the RPE was reduced to basal
levels by 30 µM AG1024.
Figure 4B demonstrates a similar effect in Müller cell cul-
tures. In the presence of 15 mM glucose, 9 nM insulin re-
duced GFAP expression by 48±11%, (p<0.05) and this was
significantly inhibited by 30 µM AG1024, increasing GFAP
expression to baseline levels. Addition of 120 µM AG1024
had no additional effect on GFAP expression. Treatment with
1 nM IGF caused a decrease in GFAP expression of 58±9%
(p<0.05), similar to that induced by 9 nM insulin. The IGF-
induced reduction of GFAP was inhibited by 30 µM AG1024
to levels observed in the absence of insulin.
DISCUSSION
 The experiments detailed here show that FGF-2 expression is
decreased in the RPE after 15 weeks of diabetes in an experi-
mental model. Surprisingly, this decrease is not correlated with
retinal FGF-2 production but showed instead a strong correla-
tion with retinal GFAP levels, a marker of glial cell activa-
tion. While a causal effect of one phenomenon upon the other
is a possibility, it is more likely that the statistical correlation
results from a dose-dependent effect of a separate factor re-
sponsible for both observations.
To explore these possibilities, primary cultures of RPE
cells and Müller cells (the primary source of GFAP in the dia-
betic retina) [7,8] were carried out. Addition of a hormonally
defined medium to achieve insulin-free culture conditions and
high glucose (15 mM) led to significantly reduced levels of
FGF-2 in RPE cells and increased GFAP levels in Müller cells,
reflecting the findings in vivo. Insulin reversed both effects in
cultures in an environment of 15 mM glucose in a dose-de-
pendent manner. The effect of insulin was mimicked by IGF,
and both influences were blocked by a specific inhibitor of
IGFR-1.
Streptozotocin-induced diabetes in the rat:  The animals
used in these experiments were pigmented Listar hooded rats,
which display pigmented RPE. Although streptozotocin-in-
duced diabetes and diabetic retinopathy is better character-
ized in other strains, the use of Listar hooded rats was found
to be necessary to assist visualizaton and handling of the RPE
during the delicate manipulations necessary to separate the
RPE sheets while avoiding choroidal contamination.
Steptozotocin appeared to induce experimental diabetes in the
rats, with increased blood glucose concentrations, polyuria,
polydipsia, cataract formation, and a failure to gain weight
noted in the diabetic group. In addition, FGF-2 and GFAP,
two proteins known to be upregulated in the diabetic retina
[4,6-8,38,39], were increased in these rats, giving an indica-
tion that diabetic retinal neuropathy was present in the samples
after 15 weeks of diabetes.
The isolation of the RPE from rats with minimal con-
tamination from the retina or choroid are shown by a lack of
retinal and choroidal markers in the sample. FGF-2 mRNA
and protein were detected in the RPE samples, and were
downregulated in the diabetic rats. Initially it could be con-
sidered that this was the logical result of increased FGF-2 ex-
pression in the retina causing a paracrine negative feedback
loop with the RPE, but no correlation was found between FGF-
2 protein levels in each retina and FGF-2 expression in the
adjacent RPE. However, GFAP, a marker known to be induced
in Müller cells in diabetes, was found to correlate with RPE
FGF-2 protein expression. Cell cultures were chosen to inves-
tigate this relationship since possible confounding factors cen-
tral to the disease, such as ischemia, can be controlled. In these
studies, the culture medium was manipulated to reflect the
core metabolic insults known to occur in type 1 diabetes: low
insulin (<36 pM) and high glucose (>5 mM).
Insulin-free conditions were required for treatment of
Müller cell cultures with “diabetic” levels of glucose (15 mM)
to mirror the changes in GFAP noted in the streptozotocin-
induced diabetic rat retina. The effect was reversed in a dose-
dependent manner by the addition of insulin, with GFAP ex-
pression returning to levels equivalent to those of cultures
grown in 5 mM glucose when treated with physiological con-
centrations of insulin (36-179 pM) [45]. Cultures displayed
less GFAP expression than cultures grown in 5 mM glucose
even when treated with supraphysiological levels of insulin.
Care should be taken in correlating these results with the con-
ditions of hyperinsulinaemia or type 2 diabetes, where insulin
resistance and receptor malfunction is the primary defect [1].
“Diabetic” glucose levels in insulin-free conditions also
decreased FGF-2 production in cultured human RPE cells, mir-
roring the results presented in the animal model and perhaps
indicating that the phenomenon may extend to human disease.
Once again, this effect was reduced with the addition of physi-
ological levels of insulin, which restored FGF-2 expression to
levels equivalent to those of cultures grown in 5 mM glucose.
The results also indicate that the trend continues with supra-
physiological insulin treatments, but care should again be taken
in extending this analysis to the type 2 diabetic situation for
the reasons already given.
The results also demonstrate that no concentration of glu-
cose or insulin tested produced a significant change in Müller
cell FGF-2 production. While acknowledging the inherent er-
rors in using monolayers of isolated, transformed, actively di-
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viding or passaged cells in investigations, these results together
support the hypothesis that high glucose levels in the absence
of insulin contribute to both the increased GFAP expression
in the retina (which is mostly of Müller cell origin) [6], and
decreased FGF-2 production in the RPE. Therefore, the com-
bined effects of low insulin and high glucose could account
for the correlation between the retinal GFAP and RPE FGF-2
noted in the streptozotocin-induced diabetic rat. Therefore, this
may be an important contributor to similar observations in the
human condition.
The insulin receptor (IR) is known to be present in the
CNS [47] and in the retina [48], where it appears to be local-
ized in photoreceptors, other neuronal elements [49], and in
the RPE [50]. However, the retina is unusual in that IGF bind-
ing is 10-20 times greater than insulin binding [51]. Like in-
sulin and IGF-1, the IR and IGFR-1 display extensive struc-
tural homologies [52,53], with both insulin and IGF acting as
ligands for each, although the extent of the modest cross-af-
finity of each substance to the other receptor is controversial.
Binding studies suggest each ligand has a 100 fold increased
affinity for its own receptor [54,55]; however, studies of bind-
ing and pharmacological effects of the ligands in the retina
estimate up to a 30 fold greater cross reactivity than these re-
sults predict [51,56,57]. This may be due to nonclassical insu-
lin binding patterns that have been reported in the retina, where
a proportion of binding sites have a similar affinity for both
IGF and insulin [51]. Given the presence of both the IR and
IGFR1 in the RPE and retina, the unusually high cross-reac-
tivity between the two and the fact that the literature supports
the strong possibility of a differential regulation of FGF-2 and
IGF-1 [58-60], it was hypothesized that the effect of insulin
on FGF-2 and GFAP could be modulated through the IGFR-1
receptor.
This hypothesis was supported by the investigations pre-
sented here, in which treatment with AG1024 at a concentra-
tion known to specifically inhibit IGFR-1 [46] blocked the
effect of insulin on FGF-2 expression in cultured RPE cells
and its effect on GFAP expression in cultured Müller cells. In
addition, treatment with IGF at a concentration ten times lower
than that tested for insulin resulted in an effect of the same
magnitude on both cell types. This effect was also blocked by
the IGFR-1 receptor blocker AG1024. Addition of AG1024 at
the much higher concentration necessary to also block the IR
[46] had no further influence on either RPE FGF-2 expression
or Müller cell GFAP expression. This evidence may be inter-
preted to support the tentative conclusion that the dose-de-
pendent effect of insulin on RPE FGF-2 production and Müller
cell GFAP production is mediated through the IGFR-1 rather
than, as originally expected, the IR.
These results could explain the findings that treatment of
cultures with diabetic levels of glucose is a prerequisite for
the withdrawal of insulin to induce phenotypical changes in
RPE and Müller cells. Previous studies have reported that IGF-
induced pancreatic b cell proliferation is glucose dependent,
displaying maximal synergy at 15 mM of glucose [61]. Simi-
larly, IGF and glucose have been observed to act synergisti-
cally in stimulating fibrosis in renal fibroblasts [62], contrib-
uting to diabetic nephropathy. It appears consistent to argue
that, in the culture experiments, insulin acts in synergy with
“diabetic” glucose levels through the IGFR-1 receptor to alter
RPE FGF-2 expression and Müller cell GFAP expression. This
mechanism could induce similar changes consistent with the
observations presented here in the streptozotocin-induced ro-
dent model of diabetic retinal neuropathy and with the known
manifestations of diabetes in retinal glial cells in human dia-
betes [8].
It should be noted that the IGF system is complex in the
intact retina and consists of at least insulin, IGF-1, IGF-2, and
the primarily inhibitory IGF binding proteins 2 and 3 [63]. In
addition, it is known that IGF itself has an important role in
diabetes. IGF is downregulated in the retina of diabetic rats
[64]. In contrast, IGF is upregulated in the diabetic vitreous
after the onset of microvascular disease [65] and appears to
be disproportionally active at this stage of the disease [66].
Additionally, IGF is important in upregulating VEGF expres-
sion in the diabetic retina [67], and IGFR-1 receptors are re-
quired for retinal neovascularization in a neonatal hypoxia
model [68]. Recent data from a normoglycemic transgenic
model overexpressing IGF reported that the model displays
most of the signs of human diabetic retinopathy [69]. Together
these reported results imply that IGF is decreased in the
streptozotocin-induced diabetic retinal neuropathy in the rat
and possibly the human, but an increase may mark the onset
of neovascularization in both the rat and human [69]. There-
fore, changes in IGF appear to be complex and pathogeni-
cally important in the diabetic retina. Indeed these experiments
do not rule out the possibility that autocrine production of IGF
in the culture systems may have contributed to some of the
effects noted here; however, it was not the purpose of these
experiments to fully investigate the IGF system in the dia-
betic retina and RPE. It is worth noting that the previously
described decrease in retinal IGF levels reported in diabetes
would be expected to exacerbate the effects of low insulin on
Müller cell GFAP expression and RPE FGF-2 levels in a dia-
betic environment through this mechanism.
It is concluded that low insulin, high glucose environ-
ments in culture mirror phenotypical changes in an animal
model of experimental diabetes. It is likely that decreased ac-
tivation of the IGFR-1 in diabetes contributes, perhaps sig-
nificantly, to the retinal effects of the disease.
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